Stockreport

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical developm [Read more]